NASDAQ:EDIT Editas Medicine Q4 2025 Earnings Results & Report $2.35 -0.09 (-3.69%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$2.39 +0.04 (+1.74%) As of 10/16/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Editas Medicine beat analyst expectations on both earnings and revenue in its Q4 2025 results, released March 9, 2026. The company reported EPS of -$0.06 versus the -$0.27 consensus estimate, while revenue of $24.74 million topped the $8.77 million estimate by $15.97 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 9, 2026TimeBefore Market OpensConference Call7:00 AM ET Editas Medicine EPS ResultsActual EPS-$0.06Consensus EPS -$0.27Beat/MissBeat by +$0.21One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersEditas Medicine Revenue ResultsActual Revenue$24.74 millionExpected Revenue$8.77 millionBeat/MissBeat by +$15.97 millionYoY Revenue GrowthN/AUpcoming EarningsEditas Medicine's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 3, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Editas Medicine Q4 2025 Earnings FAQ Did Editas Medicine beat earnings estimates for Q4 2025? Editas Medicine (NASDAQ:EDIT) reported earnings of -$0.06 per share for Q4 2025, beating the consensus estimate of -$0.27. The report was announced on Monday, March 9, 2026. What was Editas Medicine's revenue for Q4 2025? Editas Medicine reported revenue of $24.74 million for Q4 2025, against a consensus estimate of $8.77 million. When is Editas Medicine's next earnings date? Editas Medicine's next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Editas Medicine on the company's earnings history page. Editas Medicine Earnings HeadlinesEditas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor ConferenceOctober 14 at 3:09 PM | finance.yahoo.comEditas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor ConferenceOctober 14 at 9:00 AM | globenewswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic ShiftOctober 12, 2026 | seekingalpha.comEditas Medicine (NASDAQ: EDIT) clears EDIT-401 for first-in-human trial in AustraliaOctober 11, 2026 | americanbankingnews.comEDIT Set to Begin First-in-Human Study in HypercholesterolemiaOctober 9, 2026 | finance.yahoo.comSee More Editas Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Editas Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Editas Medicine and other key companies, straight to your email. Email Address About Editas MedicineEditas Medicine (NASDAQ:EDIT) is a biotechnology company focused on developing genomic medicines that use CRISPR-based gene-editing technologies to treat diseases caused by genetic abnormalities. The company’s research programs are designed to modify or correct disease-associated genes in patients’ cells, with the goal of developing potentially durable treatments. Its lead investigational program is reni-cel, formerly known as EDIT-301, an ex vivo CRISPR gene-editing therapy being studied for sickle cell disease and transfusion-dependent beta thalassemia. Editas has also pursued additional programs involving both ex vivo and in vivo gene editing, including potential treatments for genetic diseases affecting the blood and eyes. These therapies remain investigational and are subject to clinical and regulatory evaluation. Founded in 2013 and headquartered in Cambridge, Massachusetts, Editas Medicine conducts research and clinical development activities intended to serve patients internationally. The company was established by researchers and biotechnology industry professionals, including prominent scientists associated with the development of CRISPR gene-editing technology. Its business is centered on advancing proprietary gene-editing platforms and translating them into medicines for serious diseases with limited treatment options.View Editas Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bank of America Stock Sell-Off Looks Like a Buying OpportunityMorgan Stanley Beats on Earnings, But Shares Fall on Trading MixFundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?Palantir's Potential Next Catalyst After Retail Profit-TakingApple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
